[EN] PYRAZOLOPYRIMIDINE DERIVATIVES AND USES THEREOF AS TET2 INHIBITORS [FR] DÉRIVÉS DE PYRAZOLOPYRIMIDINE ET LEURS UTILISATIONS EN TANT QU'INHIBITEURS DE TET2
摘要:
The present invention relates to novel pyrazolopyrimidine compounds that are TET2 inhibitors, processes for their preparation, pharmaceutical compositions, and medicaments containing them, and their use in diseases and disorders mediated by a TET2 inhibitor.
[EN] PYRAZOLOPYRIMIDINE DERIVATIVES AND USES THEREOF AS TET2 INHIBITORS [FR] DÉRIVÉS DE PYRAZOLOPYRIMIDINE ET LEURS UTILISATIONS EN TANT QU'INHIBITEURS DE TET2
摘要:
The present invention relates to novel pyrazolopyrimidine compounds that are TET2 inhibitors, processes for their preparation, pharmaceutical compositions, and medicaments containing them, and their use in diseases and disorders mediated by a TET2 inhibitor.
[EN] PYRIMIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRIMIDINE
申请人:IDORSIA PHARMACEUTICALS LTD
公开号:WO2018210992A1
公开(公告)日:2018-11-22
The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R5b, and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (III) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
[EN] PYRAZOLOPYRIMIDINE DERIVATIVES AND USES THEREOF AS TET2 INHIBITORS<br/>[FR] DÉRIVÉS DE PYRAZOLOPYRIMIDINE ET LEURS UTILISATIONS EN TANT QU'INHIBITEURS DE TET2
申请人:[en]NOVARTIS AG
公开号:WO2023214325A1
公开(公告)日:2023-11-09
The present invention relates to novel pyrazolopyrimidine compounds that are TET2 inhibitors, processes for their preparation, pharmaceutical compositions, and medicaments containing them, and their use in diseases and disorders mediated by a TET2 inhibitor.